Novalpina Capital

Increasingly litigious interactions and overt hostility at Novalpina has increased the appeal of a possible third-party replacement, PEI understands.

The blow-up between founders of Novalpina Capital is a rare thing. We dig deeper into what constitutes a GP removal.

Novalpina's LPAC is in a hurry to find a replacement GP for the firm's debut fund. Plus: a look at the biggest trends shaping PE healthcare strategies during the pandemic and ILPA has published an ESG assessment framework. Here's today's brief, for our valued subscribers only.

How savvy sponsors are using data science to improve outcomes from deal origination to due diligence and value creation. Plus: Australia's Future Fund could be in for a SPAC-tacular investment return and China's Legend Capital is back on the fundraising trail. Here's today's brief, for our valued subscribers only.

The independent European private equity firm has closed its first fund at target.

Novalpina's former IR boss has resurfaced in France. Plus: Tikehau has tapped NYCRS for its growing climate business, and private equity is on a hiring spree in India. Here's today's brief, for our valued subscribers only.

The fundraisers turning investors’ heads and attracting capital commitments.

Campbell Lutyens wants to help Chinese GPs raise more capital in a regulation-restricted environment. Here’s today's brief, for our valued subscribers only.

US managers gathered four of the largest fundraises last month raising almost $11bn among them.